| Literature DB >> 29996945 |
Ying Li1, Xiu-Liang Cui2,3, Qing-Shan Chen1, Jing Yu1, Hai Zhang4, Jie Gao5, Du-Xin Sun6, Guo-Qing Zhang7.
Abstract
BACKGROUD: Cationic liposomes (CLs) can be used as non-viral vectors in gene transfer and drug delivery. However, the underlying molecular mechanism of its cytotoxicity has not been well elucidated yet.Entities:
Keywords: Cationic liposomes; Cytotoxicity; Lipid metabolism; Nanoparticle; RNA-seq
Mesh:
Substances:
Year: 2018 PMID: 29996945 PMCID: PMC6042442 DOI: 10.1186/s40360-018-0230-5
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Primer sequences for quantitative Real-time reverse transcription-PCR (qRT-PCR) assay
| Gene | Primer sequences (5′-3′) |
|---|---|
| PLA2G3 | Forward:AGAGAGGATGGACCATGCCT |
| SLC27A6 | Forward: TCCTGTGGGCTTTTGGTTGT |
| HOGA1 | Forward: GGATCCCAGGGCTGAAGAAA |
| DAPK1 | Forward: AAGATCAAGTGCTGCCTGCT |
| NFKBIZ | Forward: GCCCAGTTGCCTGTCTTTTG |
| DHCR7 | Forward: CCAGGTGCTTCTGTACACGT |
| LSS | Forward: GAGCGGCGTTATTTGCAGAG |
| DRAM1 | Forward: CATCTCTGCCGTTTCTTGCG |
| SRD5A3 | Forward: CGAGTGCCTCTACGTCAGTG |
| AKR1C4 | Forward: CTCTCAAGCCAGGTGAGACG |
| PDK4 | Forward: AGAGGTGGAGCATTTCTCGC |
Fig. 1HepG2 cytotoxicity of CLs at a series of concentrations (exposure for 24 h)
Mapping statistics, reads distribution and quantification of RNA-seq
| Sample ID | Raw reads (million) | Unmapped reads (million) | Mapped reads (million) | Mapped ratio (%) | Uniquely mapped ratio (%) |
|---|---|---|---|---|---|
| Control-1 | 15.20 | 1.94 | 13.26 | 87.2 | 83.5 |
| Control-2 | 15.25 | 2.09 | 13.16 | 86.3 | 82.7 |
| Control-3 | 15.15 | 1.93 | 13.23 | 87.3 | 83.5 |
| CLs-1 | 19.16 | 3.18 | 15.98 | 83.4 | 79.2 |
| CLs-2 | 15.11 | 1.98 | 13.13 | 86.9 | 83.0 |
| CLs-3 | 14.72 | 1.87 | 12.85 | 87.3 | 83.5 |
Fig. 2a Expression profile heat map of DEGs in HepG2 cells following exposure to CLs. A total of 77 up-regulated and 143 down-regulated genes are shown. b GO analysis of DEGs. c GO tree analysis of enriched GO terms. Red circles represent up-regulated genes; Green circles represent down-regulated genes; Yellow circles represent ambiguous-regulated genes
Gene regulated by cationic liposomes in the HepG2 cell
| Gene ID | Gene Symbol | Description | Log2FC | FDR |
|---|---|---|---|---|
| 50,487 | PLA2G3 | Group 3 secretory phospholipase A2 | −3.02 | 2.88E-02 |
| 28,965 | SLC27A6 | cDNA, FLJ94000, highly similar to | −1.47 | 7.5E-03 |
| 112,817 | HOGA1 | 4-hydroxy-2-oxoglutarate aldolase, mitochondrial | −1.23 | 3.6E-03 |
| 1612 | DAPK1 | Death-associated protein kinase beta | −1.20 | 0 |
| 64,332 | NFKBIZ | NF-kappa-B inhibitor zeta | −1.04 | 1E-05 |
| 7108 | TM7SF2 | Transmembrane 7 superfamily member 2, isoform CRA_a | −0.95 | 9.9E-03 |
| 1717 | DHCR7 | 7-dehydrocholesterol reductase, isoform CRA_a | −0.82 | 5.18E-11 |
| 4047 | LSS | cDNA, FLJ92849, highly similar to Homo sapiens lanosterol synthase (2,3-oxidosqualene-lanosterolcyclase) (LSS), mRNA | −0.66 | 1.59E-05 |
| 55,332 | DRAM1 | DNA damage-regulated autophagy modulator protein 1 | −0.60 | 4.44E-02 |
| 79,644 | SRD5A3 | Polyprenolreductase | 0.75 | 2.75E-04 |
| 1109 | AKR1C4 | Aldo-ketoreductase family 1 member C4 | 1.00 | 6.59E-07 |
| 3162 | HMOX1 | Heme oxygenase 1 | 1.21 | 3.12E-03 |
| 5166 | PDK4 | Pyruvate dehydrogenase kinase, isoenzyme 4 | 2.54 | 0 |
Gene Ontology (GO) categories of differentially expressed genes (DEGs)
| GO ID | Term | Total | Significant | Genes | P-value |
|---|---|---|---|---|---|
| GO: 0008202 | steroid metabolic process | 122 | 15 | INSIG1, DHCR7, AKR1C4, SRD5A3, PCSK9, MVD, APOA1, LDLR, MVK, HSD3B2, HSD11B1, STAR, TM7SF2, LSS, SULT1A3 | 6.79E-12 |
| GO: 0006695 | cholesterol biosynthetic process | 34 | 7 | INSIG1, DHCR7, MVD, APOA1, MVK, TM7SF2, LSS | 1.08E-07 |
| GO: 0008203 | cholesterol metabolic process | 89 | 9 | INSIG1, DHCR7, PCSK9, MVD, APOA1, LDLR, MVK, STAR, TM7SF2 | 4.28E-07 |
| GO: 0042542 | response to hydrogen peroxide | 43 | 7 | OLR1, GNAO1, HMOX1, HBA1, HBB, STAR, | 4.43E-07 |
| GO: 0006694 | steroid biosynthetic process | 60 | 7 | DHCR7, MVD, MVK, HSD3B2, STAR, TM7SF2, LSS | 3.35E-06 |
| GO: 0044281 | small molecule metabolic process | 1410 | 34 | ANGPTL4, PIK3C2B, ABCB1, INSIG1, FHL2, KYNU, ALDH1A1, DHCR7, HMOX1, HBA2, HBA1, PLA2G3, GPAT3, ACSS2, AKR1C4, HBB, SRD5A3, GLUL, SLC25A20, MVD, PDK4, APOA1, G0S2, LDLR, MVK, HSD3B2, GCLC, BGN, SLC2A3, HSD11B1, STAR, TM7SF2, LSS, SULT1A3 | 4.28E-06 |
| GO: 0016126 | sterol biosynthetic process | 29 | 5 | INSIG1, DHCR7, MVD, MVK, TM7SF2, | 1.55E-05 |
| GO: 0006629 | lipid metabolic process | 490 | 16 | INSIG1, DHCR7, FA2H, PLA2G3, AGPAT9, SRD5A3, PCSK9, MVD, APOA1, LDLR, SLC27A6, MVK, HSD11B1, TM7SF2, LSS, SULT1A3 | 3.91E-05 |
| GO: 0007010 | cytoskeleton organization | 7 | 117 | KRT4, NEDD9, THY1, WTIP, RHOU, KRT8, CNN2 | 1.80E-04 |
| GO: 0045766 | positive regulation of angiogenesis | 6 | 88 | ANGPTL4, ECM1, HMOX1, GREM1, GATA6, ANXA3 | 2.65E-04 |
Fig. 3a Pathway analysis of DEGs. Red represents the significant pathway. b Pathway act network. c Gene act network
Fig. 4Co-expression network of DEGs in the control (a) and CLs-treated (b) groups. Solid lines represent positive correlation, and dashed lines represent negatively correlation. The size and color of the nodes correspond to their co-expression ability. The greater the size of the node, the greater the number of its direct neighbors
Intersection of DEGs between control and CLs-treated groups
| Gene | Degree | K-core | Dif Degree | Dif K-core | ||
|---|---|---|---|---|---|---|
| control | CLs-treated | control | CLs-treated | |||
| G0S2 | 0 | 38 | 0 | 32 | 38 | 32 |
| HSD11B1 | 0 | 38 | 0 | 32 | 38 | 32 |
| HSD3B2 | 0 | 38 | 0 | 32 | 38 | 32 |
| CXCL5 | 0 | 38 | 0 | 32 | 38 | 32 |
| STAR | 6 | 37 | 4 | 32 | 31 | 28 |
| FA2H | 9 | 31 | 7 | 28 | 22 | 21 |
| DHCR7 | 23 | 38 | 21 | 32 | 15 | 11 |
Fig. 5a, b qRT-PCR verification of selected DEGs including 8 down-regulated and 3 up-regulated genes. The relative expression levels of these genes were normalized to GAPDH. c HepG2 cell cycle analysis was performed by flow cytometry. The percent of cells in each phase of the cell cycle was shown
Fig. 6The schematic diagram of this study. The procedure included three steps. Firstly, the cytotoxicity of cationic liposomes (CLs) was detected in HepG2 cell and DEGs in the CLs group comparing with control were identified through next generation RNA-seq technology. Then, functional analysis and bioinformatics computing were employed to explore the key genes and pathways. Finally, expression levels of these genes were confirmed by qPCR, and the cell cycle was assessed by flow cytometry